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A b s t r a c t
The role that apoptosis plays in the pathogenesis o f amyotrophic lateral sclerosis (ALS) is still unclear. From our au­
topsy samples, we have undertaken an effort to verify if  apoptosis in ALS really occurs or if  can at least be detec­
ted. The study was performed using TUNEL method for screening the apoptotic changes in the autopsy samples 
from 8 ALS cases compared with 16 control cases. No features o f apoptosis (DNA cleavages) were noted in any of 
the investigated regions o f the central nervous system in ALS cases as well as in controls. These preliminary results 
seem to support the reports, which deny the role o f apoptosis in human ALS. The following investigations using ad­
ditional methods will be performed for detection the apoptotic signals in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressi­
ve and fatal neurodegenerative disease characteri­
zed by selective loss of motor neurons in the motor 
cortex, brainstem, and spinal cord [13]. Unfortunate­
ly, there is no in vivo, satisfactory noninvasive tool 
that has excellent performance at assessing motor 
neuron functional status or number. The mechani­
sms of cell death for these motor neurons still rema­
in unclear. Different hypotheses based on ALS stu­
dies in humans and on mouse models have varying 
different pathogenetic processes leading to neuro­
degeneration in ALS. Some examples of these hypo­
theses are defective function of glutamate system 
[18], oxidative stress and mitochondrial dysfunction
[2,13,23], autoimmunity or neurotrophic deficit [1,22]. 
In about 5-10% of ALS, the mutations of the cytoso­
lic Cu/Zn superoxide dismutase (SOD 1) have been 
found [5,14,18]. Recent studies suggest that the de­
generation of motor neurons in ALS could be a form
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Table I. ALS patients characteristics (n= 8)
of apoptotic cell death (programmed cell death, PCD) 
[2,3,6,8,10,12-14,23,25,26].
Apoptosis, in contrast to necrosis, a passive pro­
cess, is an energy dependent process characterized 
by cytoplasmic membrane blebbing with cytoplasmic 
chromatin condensation and fragmentation and cell 
surface alterations [23]. The induction of apoptosis 
requires the activation of specific members of CED- 
3/ICE family proteases (caspases) [8,23]. There are 
two primary pathways of apoptosis induction le­
ading to the cleavage of inactivate procaspases into 
active ”protein-killers”: (a) a pathway involving the 
activation of cell death receptors of the TNF family 
(e.g., Fas/CD95, type I TNF receptor and death recep­
tor 3) and (b) the induction of the mitochondrial pa­
thway. In the first case, coupling of death receptors 
with their ligands, leads finally to activation of pro- 
caspase-8. Activated caspase-8, in turn, switches on 
the downstream effector caspases such as caspase- 
3, -6, and -7 [10,23]. The induction of the mitochon­
drial pathway via intracellular stimuli (DNA damage 
or loss of growth factor signals), leads to the release 
of cytochrom c into the cytosol and the activation of 
apoptotic protease-activating factor-1 (Apaf-1)
[10,23]. There is rapidly increasing evidence of mito­
chondrial control of the specific apoptosis pathways 
which may play a crucial role in mechanism of death 
of motor neurons in ALS [2,3,14,19]. However, it re­
mains unknown whether neuronal death in ALS is 
due to apoptotic mechanisms. [7,23].
We have undertaken an effort to check in our 
own material whether apoptosis (DNA fragmenta­
tion) in ALS really occurs or at least whether apopto­
sis alone can be detected.
Material and methods
Frozen, unfixed samples taken during routine au­
topsies from the motor cortex, medulla and spinal 
cord of 8 patients who died from sporadic (no posi­
tive familial history of the disease) ALS and from 16 
patients who died in years 2000-2004 due to other
diseases were stored consecutively and cryo prese­
rved in minus 80oC. In addition to the samples taken 
and stored unfixed in minus 80oC, other samples we­
re taken from the motor cortex, other regions of bra­
in hemispheres, from basal banglia, cerebellum, mid­
brain, pons, medulla and three levels of spinal cord. 
These were fixed in formalin and routinely processed 
into paraffin blocks, cut by microtome and stained 
by HE and Kluver-Barrer methods for myelin. In sli­
des from the motor cortex, medulla and spinal cord 
immunohistochemistry was applied with antibody 
against ubiquitin. In all ALS cases, patients died due 
to respiratory failure at the Neurological Department 
of Jagiellonian University in Krakow and were autop­
sy-confirmed according to El Escorial criteria [4]. Par­
ticularly, the histopathological examination of sam­
ples from spinal cords and medulla in all cases sho­
wed significant loss of motor neurons. The loss of 
neurons was predominately located in samples from 
the motor cortex and/or the typical palor of pyrami­
dal tracts in slides stained for myelin was noted. In 
most cases, ubiquitin-positive inclusions were found 
either in anterior horns of spinal cord or in motor 
nuclei of cranial nerves of the medulla. They were 
usually in the form of small cytoplasmic Bunina-bo­
dy-like or skein-type deposits. No Lewy-body type in­
clusions or any conspicuous Alzheimer-type patholo­
gy was found in any case. The control group consi­
sted of two patients with stroke, two with subdural 
haematoma, three with non-Hodgkin’s lymphoma, 
five with malignant glioma, two with metastatic tu­
mor, one with GM2-gangliosidosis, and one with Ja­
kob-Creutzfeldt disase. In all of these cases, no pa­
thology consistent with the criteria for ALS was fo­
und. Jakob-Creutzfeldt disease was confirmed both 
by typical histopathological changes and by positive 
immunohistochemistry for proteinase-resistant 
prion protein. The mean age of death was 65.2±4.2 
years in the ALS group and 63.7±2.2 years (mean 
±SD) in the control group. The differrence was not 
statistically significant. Brain tissue was taken from 
both groups with posmortem delay time between 
death and snap freezing 21±4.3 hours in ALS patients 
and 22.9±3.6 hours (mean ±SD) in the control group, 
again without significant difference (table I, II). The 
collection of brain samples were examined by TUNEL 
method for detection of apoptosis in 2004. The stu­
dy was approved by the Bioethical Committee of Ja­
giellonian University, Krakow, KBET78/B/2001.
Age at death 65.2±4.2 yr (mean ±SD) (range: 61-72 yr)
Postm ortem  delay 21±4.3 h (range: 20-23 h)
Gender fem ale n=5, male n=3
Type o f onset bulbar onset n=3 lim b onset n=5
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Table II. The control group characteristics (n=16)
A ge at death 63.7±2.2 yr (m ean ±SD ) (range: 56-74 yr)
Postm ortem  delay 22.9±3.6 h, (range: 19-23 h)
G ender fem ale  n = 9 , m ale n=7
Type o f d isease stroke n =2, sub du ra l haem ato m a n =2, n o n -H o d g k in ’s lym phom a n =3, m alig n a n t g lio m a n=5, 
m etastatic  tu m o r n =2, G M 2 -g a n g lio sid o sis  n=1, Jako b -Creutzfe ld t d ise ase  n=1
TUNEL method
Cleavage of genomic DNA during apoptosis may 
yield double-stranded, low molecular weight DNA 
fragments (mono- and oligonucleosomes) as well as 
single strand breaks ('nicks') in high molecular we­
ight DNA. Those DNA strand breaks can be identi­
fied by labeling free 3’-OH termini with modified 
nucleotides in an enzymatic reaction.
Terminal deoxynucleotidyl transferase (TdT), 
which catalyzes polymerization of nucleotides to 
free 3’-OH DNA ends in a template-independent 
manner, is used to label DNA strand breaks. Fluore­
scein labels incorporated in nucleotide polymers we­
re detected and quantitated by fluorescence micro­
scopy. Frozen tissue sections were fixed for 20 minu­
tes in 4% paraformaldehyde solution and washed 
twice for 30 minute in PBS at room temperature.
Slides were incubated in permeabilisation solu­
tion (0.1% TritionX100, 0.1% sodium citrate) for two 
minutes on ice and rinsed twice in PBS. Fifty millili­
ters of TUNEL reaction mix was added and slides 
were incubated for 60 minutes in a humidified dark 
chamber. Slides were rinsed three times in PBS. All 
TUNEL slides were screened directly for apoptotic 
neurons changes using the fluorescent microscope- 
-computer system.
Results
Although significant neuron loss was evident in 
ALS cases, no features of apoptosis (DNA cleavages) 
were detected in any of the investigated regions of 
the central nervous system in ALS cases as well as in 
controls. In many neurons, conspicuous lipofuscin 
deposits with strong yellowish fluorescence were 
noted (see Fig. 1-7).
Discussion
Utilization of the TUNEL method demonstrated 
no features of apoptosis (DNA cleavages) in any of
the samples taken during autopsy from the motor 
cortex, medulla, and spinal cord of 8 ALS patients. 
No apoptosis was also deteted in any of the compa­
tible brain samples taken from the motor cortex, 
medulla, and spinal cord of the control group. There­
fore, the question arises whether apoptosis is invo­
lved in neurodegeneration of human ALS, or whe­
ther we are unable to detect the apoptotic changes.
Rg. L  ALS -  anterior horn. Only one preserved 
large motor neuron is visible. Obj. magn. 20x
Fig. 2. ALS -  anterior horn. A group of motor neu­
rons, some of them rich in lipofuscin and sho­
wing different stages of degeneration, but appa­
rently not signs of apoptosis. Obj. magn. 20x
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Fig. 3. ALS -  anterior horn. One of 2 motor neu­
rons is being disintegrated but apparently not 
due to apoptosis. Obj. magn. 40x
Fig. 4. ALS -  anterior horn. Degeneration of mo­
tor neurons with chromatolysis and with lipofu­
scin overloading (relatively typical findings in 
ALS). Obj. magn. 40x
Fi& 5. ALS -  motor cortex. Loss of neurons. Obj. 
magn. 20x
Most of the evidence suggesting a role for apop­
tosis in ALS involves study of the SOD1 protein using 
in vitro and mouse models [8,10,12-14]. There are 
conflicting data regarding the occurrence of apopto­
tic pathways in ALS in humans in the literature. In 
a chronic neurodegenerative disease such as ALS, 
conclusive evidence of apoptosis is likely to be diffi­
cult to detect, given the rapidity of the apoptotic cell 
death process in relation to the relatively slow time 
course of the disease [10]. However, Yoshiyama [29] 
has detected DNA fragmentation in autopsy spinal 
cord samples only from 9 ALS patients, but not in ten 
control samples. Also, Troost et al. [25,26] reported 
that examination of ALS spinal cord has shown evi­
dence for apoptosis by TUNEL stain. Supportive stu­
dies of apoptotic related proteins have revealed de­
creased antiapoptotic Bcl-2 mRNA and increased pro- 
apoptotic Bax mRNA in spinal neurons [25,26]. Also 
Troost et al. [25] have found immunocytochemically 
increased Bcl-2 in the nuclei of neurons and in their 
cytoplasm in brain and spinal cord of ALS patients. 
Ekegren et al. [6] have showed upregulation of the cell 
death promoting protein Bax and increased DNA de­
gradation, indicative of apoptosis, in spinal motor 
neurons of ALS patients. Martin et al. [13] detected 
the occurrence of intranucleosomal DNA fragmenta­
tion in affected ALS brain region (motor cortex, spinal 
cord) but not in spared brain regions such as somato­
sensory cortex. These results were confirmed by de­
tection of intranucleosomal fragmentation of DNA in 
anterior horn gray matter of the spinal cord and mo­
tor cortex from ALS cases by gel electrophoresis [13].
In contrast, Migheli et al. [16,17] have failed to 
provide any evidence of intranucleosomal cleavage 
of DNA in postmortem tissue from human and ani­
mal ALS material. Also, He and Strong [9] reported 
that degenerating motor neurons in ALS, identified 
by ubiquitin immuno-reactivity, did not demonstra­
te the morphological characteristic of apoptosis and 
were not TUNEL positive or c-Jun immunoreactive. 
They demonstrated the lack of apoptosis in ALS spi­
nal motor neurons and suggested that this observa­
tion does not relate to the utilization of post-mor­
tem tissue in which apoptotic neurons may have be­
en lost [9]. In 2001, Emabcher et al. [7], also did not 
find evidence for apoptosis as a major mechanism 
of motor neuronal cell death in sporadic ALS. They 
were studying the expression and distribution pat­
terns of pro- and anti-apoptotic bcl-2 family mem-
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bers as well as the executioner caspase-3 in post­
m ortem brain tissue of 8 sporadic ALS patients and 
7 age-matched controls. The authors found that 
sparse motor neurons were immunoreactive for Bcl- 
2, Bax, Bak, and CM1 on serial sections through the 
spinal cord and motor cortex of singular ALS pa­
tients and controls, although there was no signifi­
cant difference in the number of immunoreactive 
neurons between ALS and control groups.
Although the role of apoptosis in the loss of mo­
tor neurons in humans ALS remains controversial 
the presented results seem to support the reports, 
which deny the role of apoptosis processes in hu­
man ALS [7,9,16,17]. This observation was also con­
firmed by negative results of clear apoptotic chan­
ges in human material from different neurodegene­
ration diseases such as PD and LBD [11,24,27,28]. On 
the other hand, it is noteworthy to mention that 
though TUNEL is a popular method for the detection 
of apoptotic cells, DNA fragmentation detected by in 
situ method (e.g., TUNEL) also occurs in nonapopto- 
tic cell death such as necrosis [8]. Thus, the TUNEL 
method, a sensitive tool for detection of apoptosis, 
should be granted with limited credit.
Conclusions
Either apoptosis (detected by TUNEL) is not invo­
lved in pathogenesis of ALS, or the process of apop­
tosis is absent in the terminal stage of disease or el­
se it is simply extremely elusive. The chances of cat­
ching 'a suspected culprit' may be small considering 
that apoptosis is a relatively rapid phenomenon and 
at the terminal stage of disease not many neurons 
remain in the most 'sensitive' regions of the central 
nervous system.
The presented study is a part of our ongoing 
work on the occurrence of apoptotic neurons chan­
ges and expression of pro-apoptotic, BH3 only prote­
ins from the Bcl-2 protein family and their role in the 
induction of mitochondrial apoptosis in ALS.
Future directions
We are studying the expression of mRNA of Bcl-2, 
Bcl-x (L), Bax, Bad, Bak, Bid, Bik and ICE/kaspazy-1 
by using rt-PCR method, and the expression of anti- 
and proapoptotic (BCl-2 and Bcl-x (L) and Bax, Bad, 
Bak, Bid, Bik) proteins as well as the expression of 
the proteolytic proteins by using Western-blot now. 
The results will be published soon.
Fig. 6. Control case, -  motor cortex. There is no
apparent loss of neurons. Obj. magn. 20x
Fig. 7. Control case, anterior horn. No signs of 
the loss of neurons. Obj. magn. 40x
Acknowledgements
The work has been supported by grants from Po­
lish Committee for Scientific Research (No KBN 
3 P05A 014 22 and KBN 7-T11E-020-21) and NIH 
NS36821 for SK.
References
1. Appel SH. A unifying hypothesis for the cause of amyotrophic 
lateral sclerosis, parkinsonism , and Alzheim er disease. Anr 
Neurol 1981; 6: 499-505.
2. Beal MF M itochondria and the pathogenesis of ALS. Brain 
2000; 123: 1291-1292.
3. Borthwick GM, Johnson MA, Ince PG, Shaw  PJ, Turnbull DM. M i­
tochondrial enzyme activity in am yotrophic lateral sclerosis: 
im plications for the role of mitochondria in neuronal cell death. 
Ann Neurol 1999; 46: 787-790.
4. Brooks. El Escorial World Federation of Neurology criteria for 
the d iagnosis of am yotrophic lateral sclerosis. Subcom m ittee
Folia Neuropathologica 2005 ; 43/2 79
Barbara Tomik, Dariusz Adam ek, Piotr Pierzchalski, Steven Banares, Aleksandra Duda,
Dorota Partyka, W iesław  Pawlik, | Józef Kałuża], Stan Krajewski, Andrzej Szczudlik
on Motor Neuron Diseases/Am yotrophic Lateral Sclerosis of 
the World Federation of Neurology Research Group on Neuro­
m uscular D iseases and the El Escorial 'Clinical lim its of am y­
otrophic lateral sclerosis' workshop contributors. J Neurol Sci 
1994; 124 Suppl: 96-107.
5. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY 
Getzoff ED, Hu P, Herzfeldt B, Roos RP Am yotrophic lateral scle­
rosis and structural defects in Cu, Zn superoxide dismutase. 
Science 1993; 261: 1047-1051.
6. Ekegren T, Grundstrom E, Lindholm D and Aquilonius SM. Upre- 
gulation of Bax protein and increased DNA degradation in ALS 
spinal cord motor neurons Acta Neurol Scand 1999; 100: 317-321.
7. Em bacher N, Kaufm ann WA, Beer R, Maier H, Jellinger KA, Po- 
ewe W, Ransm ayr G. Apoptosis signals in sporadic amyotrophic 
lateral sclerosis: an im m unocytochem ical study. Acta Neuropa- 
thol (Berl) 2001; 102: 426-434.
8. Guegan C, Przedborski S. Programmed cell death in am yotro­
phic lateral sclerosis. J Clin Invest 2003; 111: 153-161.
9. He BP, Strong MJ. Motor neuronal death in sporadic amyotrophic 
lateral sclerosis (ALS) is not apoptotic. A comparative study of ALS 
and chronic aluminium chloride neurotoxicity in New Zealand 
white rabbits. Neuropathol Appl Neurobiol 2000; 26: 150-160.
10. Honig LS, Rosenberg RN. Apoptosis and neurologic disease. Am 
J Med 2000; 108: 317-330.
11. Jellinger KA. Cell death m echanism s in Parkinson’s disease. 
J Neural Transm 2000; 107: 1-29.
12. Julien JP, Beaulieu JM. Cytoskeletal abnorm alities in am yotro­
phic lateral sclerosis: beneficial or detrim ental effects? J Neurol 
Sci 2000; 180: 7-14.
13. Martin LJ, Kaiser A, Price AC. Motor neuron degeneration after 
sciatic nerve avulsion in adult rat evolves with oxidative stress 
and is apoptosis. J Neurobiol 1999; 40: 185-201.
14. Martin LJ. p53 is abnorm ally elevated and active in the CNS of 
patients with am yotrophic lateral sclerosis. Neurobiol Dis 2000; 
7: 613-622.
15. Martin LJ, Price AC, Kaiser A, Shaikh AY, Liu Z. M echanisms for neu­
ronal degeneration in amyotrophic lateral sclerosis and in models 
of motor neuron death (Review). Int J Mol Med 2000; 5: 3-13.
16. Migheli A, Cavalla P, Marino S, Schiffer D. A study of apoptosis in 
normal and pathologic nervous tissue after in situ end-labeling of 
DNA strand breaks. J Neuropathol Exp Neurol 1994; 53: 606-616.
17. Migheli A, Atzori C, Piva R, Tortarolo M, Girelli M, Schiffer D, 
Bendotti C. Lack of apoptosis in mice with ALS. Nat Med 1999; 
5: 966-967.
18. M ulder DW, Kurland LT, Offord KP, Beard CM. Familial adult m o­
tor neuron disease: am yotrophic lateral sclerosis. Neurology 
1986; 36: 511-517.
19. Robberecht W. Oxidative stress in am yotrophic lateral sclerosis. 
J Neurol 2000; 247 Suppl 1: I1-6.
20. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hen­
tati A, Donaldson D, Goto J, O ’Regan JP, Deng HX. M utations m 
Cu/Zn superoxide dism utase gene are associated with fam ilial 
am yotrophic lateral sclerosis. Nature 1993; 362: 59-62.
21. Rothstein JD. Excitotoxicity and neurodegeneration in amyotro­
phic lateral sclerosis. Clin Neurosci 1995-96; 3: 348-359.
22. Sm ith RG, Siklos L, Alexianu ME, Engelhardt JI, M osier DR, Co­
lom L, Habib Mohamed A, Appel SH. Autoim m unity and ALS. 
Neurology 1996; 47 (4 Suppl 2): S40-5.
23. Strong MJ. The basic aspects of therapeutics in am yotrophic la­
teral sclerosis. Pharmacol Ther 2003; 98: 379-414.
24. Tatton WG, Chalm ers-Redm an R, Brown D, Tatton N. Apoptosis 
in Parkinson’s disease: signals for neuronal degradation. A m  
Neurol 2003; 53 Suppl 3: S61-70.
25. Troost D, Aten J, M orsink F and de Jong JM. Apoptosis in am y­
otrophic lateral sclerosis is not restricted to motor neurons. Bcl- 
2 expression is increased in unaffected post-central gyrus. Neu­
ropathol Appl Neurobiol 1995; 21: 498-504.
26. Troost D, Aten J, M orsink F and de Jong JM. Apoptosis in ALS is 
not restricted to motoneurons: Bcl-2 expression is increased in 
post-central cortex, adjacent to the affected motor cortex. 
J Neurol Sci 1995; 129 Suppl: 79-80.
27. Tortosa A, Lopez E, Ferrer I. Bcl-2 and Bax proteins in Lewy bo­
dies from patients with Parkinson’s disease and Diffuse Lewy 
body disease. Neurosci Lett 1997; 238: 78-80.
28. W ullner U, Kornhuber J, Weller M, Schulz JB, Loschm ann PA, 
Riederer P, Klockgether T. Cell death and apoptosis regulating 
proteins in Parkinson’s d isease-a  cautionary note. Acta Neuro­
pathol (Berl) 1999; 97: 408-412.
29. Yoshiyam a Y, Yam ada T, Asanum a K, Asahi T. Apoptosis related 
antigen, Le (Y) and nick-end labeling are positive in spinal m o­
tor neurons in am yotrophic lateral sclerosis. Acta Neuropathol 
(Berl) 1994; 88: 207-211.
80 Folia Neuropathologica 2005 ; 43/2
